ClinicalTrials.gg
RecruitingNCT07361289SOAR-HCMUpdated Nov 2, 2026

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

An observational study in Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Recruiting at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 2, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.

Planned enrollment
5th of 15
500 · median 200
Started
2026
with 4 others
Observational
15 of 32
9 open now
Primary completion
2028-08
later than 11 of 14 live
Registered
27th of 32
by date

Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 5th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 11 of the 14 other live ones, and was the 27th registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effectiveness of mavacamten treatment in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in real-world clinical practice

03

Conditions studied

  • Hypertrophic Cardiomyopathy

Keywords

  • Obstructive hypertrophic cardiomyopathy (oHCM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy that have received mavacamten treatment in China

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged ≥ 18 years (participants enrolled retrospectively: at the time of initial mavacamten prescription), irrespective of gender.
  • Participants who have initiated mavacamten (for whom enrolled retrospectively) or are scheduled to initiate mavacamten (for whom enrolled prospectively) based on clinical therapeutic needs.
  • Diagnosed with obstructive hypertrophic cardiomyopathy (HCM) consistent with current American College of Cardiology Foundation/American Heart Association, European Society of Cardiology, and Chinese guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy, i.e., satisfy criteria below:

    • Has a documented diagnosis of HCM prior to enrollment, and
    • Peak left ventricular outflow tract (LVOT) gradient ≥ 30 mmHg at rest or with provocation in the most recent medical record within 3 months prior to enrollment as assessed by echocardiography.
  • Has documented (LVEF) ≥ 55%, as measured by resting transthoracic echocardiography (TTE) in the most recent medical record within 3 months prior to enrollment.
  • (NYHA) class II or III symptoms in the most recent medical record within 3 months prior to enrollment.
  • For participants enrolled retrospectively, essential baseline information* and critical data** must be traceable and available. At least one key follow-up time points*** is required for inclusion.

Note:

* Essential baseline information, including age, gender, resting or provoked LVOT peak gradient, LVEF, indices of cardiac structure (e.g., maximum LV wall thickness, atrial and ventricular chamber size and volumes), as well as systolic and diastolic function, NYHA functional class.

  • Critical data, including resting or provoked LVOT gradient, LVEF, cardiac structure, systolic and diastolic function, dose of mavacamten.

    • Key follow-up time points: including weeks 4, 8, 12, 24, 36, 48, 72 and 96.

      • Voluntary sign form. Note: For participants enrolled retrospectively, the most recent medical record within 3 months as mentioned in the above requirements refer to the most recent medical record within 3 months prior to the initial mavacamten prescription.

Exclusion criteria

Exclusion Criteria:

  • Known HCM phenocopy disease (e.g., Fabry disease, amyloidosis).
  • Participants who are expected to undergo major cardiac surgery during the study.
  • Prior treatment of obstructive HCM with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation [ASA] or septal radiofrequency ablation) within 6 months prior to enrollment (participants enrolled retrospectively: within 6 months prior to initial mavacamten prescription); participants with an unsuccessful myectomy or percutaneous ASA or septal radiofrequency ablation performed >6 months prior to enrollment (participants enrolled retrospectively: within 6 months prior to initial mavacamten prescription) may be enrolled.
  • Currently treated with disopyramide or ranolazine (within 14 days prior to enrollment [participants enrolled retrospectively: within 14 days prior to initial mavacamten prescription]) or participants who are expected to be taking disopyramide, ranolazine, verapamil in combination with β-receptor blockers, or diltiazem in combination with β-receptor blockers during the study.
  • Presence of other diseases that may affect completion of 96 weeks follow-up as assessed by the investigator.
  • Participants who are using or are expected to be using moderate to strong CYP2C19 inhibitors/inducers, or strong inhibitors, moderate to strong CYP3A4 inducers during the study.
  • Participants who are participating in other interventional clinical studies.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten

    Drug: Mavacamten

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in Valsalva left ventricular outflow tract (LVOT) gradient

    Time frame: Week 48, Week 96

  2. Change from baseline in resting valsalva left ventricular outflow tract (LVOT) gradient

    Time frame: Week 48, Week 96

Secondary outcomes

  1. Change from baseline in New York Heart Association (NYHA) class

    Time frame: Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96

  2. Number and proportion of participants with a resting/provoked left ventricular outflow tract (LVOT) gradient < 30/50 mmHg

    Time frame: Week 12, Week 36, Week 48, Week 72, and Week 96

  3. Number and proportion of participants achieving complete response (defined as all left ventricular outflow tract (LVOT) gradients < 30 mmHg and New York Heart Association (NYHA) Class I)

    Time frame: Week 12, Week 36, Week 48, Week 72, and Week 96

07

Study locations

10 of 15 sites recruiting
  • Local Institution - 0008
    Beijing, Beijing Municipality 100029, China
    Not yet recruiting
    • Site 0008 · Contact
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100032, China
    Recruiting
    • Zhuang Tian, Site 0001 · Contact
  • Peking University First Affiliated Hospital
    Beijing, Beijing Municipality 100034, China
    Recruiting
    • Ma Wei, Site 0002 · Contact86-13681050902
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
    Recruiting
    • Yugang Dong, Site 0009 · Contact
  • The Second Afilliated Hospital of Hebei Medical University
    Jiazhuang, Hebei 050000, China
    Recruiting
    • Xinshun Gu, Site 0014 · Contact+86 13930139688
  • Local Institution - 0007
    Zhengzhou, Henan 450052, China
    Not yet recruiting
    • Site 0007 · Contact
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu 215002, China
    Recruiting
    • Yan Chen, Site 0015 · Contact+86 18015571559
  • The Second Hospital of Jilin University
    Changchun, Jilin 130041, China
    Recruiting
    • Bin Liu, Site 0004 · Contact+86043188796598
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
    Recruiting
    • Ying Liu, Site 0005 · Contact+861809887580
  • Local Institution - 0013
    Xi'an, Shan3xi 710061, China
    Withdrawn

    Not enrolling at this site.

  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
    • Yucheng Chen, Site 0012 · Contact+86 18980602149
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Recruiting
    • Xiaojie Xie, Site 0006 · Contact
  • Local Institution - 0003
    Harbin, 150086, China
    Not yet recruiting
    • Site 0003 · Contact
  • Local Institution - 0010
    Jinan, 250012, China
    Not yet recruiting
    • Site 0010 · Contact
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
    Recruiting
    • Shuning Zhang, Site 0011 · Contact+86 15921766132
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.

Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 23, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Aug 22, 2028
CompletionEst.
Aug 28, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (3 China)
  • The First Affiliated Hospital, Sun Yat-sen University · Guangzhou, China
  • The First Affiliated Hospital of Dalian Medical University · Dalian, China
  • Local Institution - 0003 · Harbin, China
Show 3 removed
  • Local Institution - 0009 · Guangzhou, China
  • Local Institution - 0003 · Harbin, China
  • Local Institution - 0005 · Dalian, China
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    3 sites added, 3 sites removed
    Show 3 added (3 China)
    • The First Affiliated Hospital, Sun Yat-sen University · Guangzhou, China
    • The First Affiliated Hospital of Dalian Medical University · Dalian, China
    • Local Institution - 0003 · Harbin, China
    Show 3 removed
    • Local Institution - 0009 · Guangzhou, China
    • Local Institution - 0003 · Harbin, China
    • Local Institution - 0005 · Dalian, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07361289
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Jan 15, 2026
Primary completion
Aug 22, 2028 (estimated)
Completion
Aug 28, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion